1. Evolution of Insulin: From Human to Analog
Joseph M. Tibaldi, MD 
The American Journal of Medicine 
Volume 127, Issue 10, Pages S25-S38 (October 2014)
DOI: /j.amjmed
Copyright © 2014 The Author Terms and Conditions

2. Figure 1
Milestones in the evolution of insulin therapy. NPH = neutral protamine Hagedorn.
The American Journal of Medicine  , S25-S38DOI: ( /j.amjmed )
Copyright © 2014 The Author Terms and Conditions

3. Figure 2
Structure of insulin glargine, insulin detemir, and insulin degludec.
The American Journal of Medicine  , S25-S38DOI: ( /j.amjmed )
Copyright © 2014 The Author Terms and Conditions

4. Figure 3
Structure of insulin lispro, insulin aspart, and insulin glulisine.
The American Journal of Medicine  , S25-S38DOI: ( /j.amjmed )
Copyright © 2014 The Author Terms and Conditions

5. Figure 4
Serum insulin levels after subcutaneous injection of (A) insulin aspart, and (B) insulin glulisine, compared with human insulin in patients with type 1 diabetes.
Adapted with permission from Lindholm et al51 and Rave et al.52
The American Journal of Medicine  , S25-S38DOI: ( /j.amjmed )
Copyright © 2014 The Author Terms and Conditions

6. Figure 5
Mean postprandial serum glucose (A) and insulin (B) profiles for patients with type 2 diabetes who received an injection of BIAsp or Mix 25 immediately before a meal or BHI 30 to 15 minutes before a meal. Reproduced with permission from Hermansen et al.72 BHI = biphasic human insulin; BIAsp = biphasic insulin aspart.
The American Journal of Medicine  , S25-S38DOI: ( /j.amjmed )
Copyright © 2014 The Author Terms and Conditions